Combination Therapy for Solid Tumors Using ACK and HDAC Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for solid tumors, particularly sarcomas and carcinomas, often require multiple therapies and have limited efficacy when using single-agent approaches, necessitating the development of combination therapies that can enhance treatment outcomes.
Innovation Solution
The co-administration of an ACK inhibitor compound, such as ibrutinib, and an HDAC inhibitor compound, like abexinostat, in various dosage forms and administration methods to synergistically target and reduce the growth or metastasis of solid tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single-agent therapy is used, then treatment simplicity is maintained, but treatment efficacy is limited
Solution Approach 1:
The patent combines two different mechanisms of action (ACK inhibitor and HDAC inhibitor) into a single combination therapy formulation. This merging of therapeutic agents allows simultaneous targeting of multiple signaling pathways (BTK/ITK/TEC kinases and histone deacetylase), thereby improving treatment efficacy while maintaining manageable therapy complexity through unified administration protocols.
2Reliability
If multiple therapies are combined, then treatment efficacy is enhanced, but treatment complexity increases
Solution Approach 1:
The combination therapy formulation is designed to achieve multiple therapeutic functions through a single administration: (1) inhibition of ACK kinases (BTK, ITK, TEC) to block signaling pathways, and (2) inhibition of HDAC to modulate gene expression. This multi-functionality is achieved through a unified compound or formulation that can be administered as a single agent, simplifying the operational complexity despite the multiple mechanisms involved.
Data Source
AI summary
Described herein are combinations of ACK inhibitors and HDAC inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.